Superselective Intra-Arterial Cerebral Infusion of Novel Agents After Blood-Brain Disruption for the Treatment of Recurrent Glioblastoma Multiforme: A Technical Case Series

Benjamin J. Shin, Jan Karl Burkhardt, Howard A. Riina, John A. Boockvar

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

Glioblastoma multiforme constitutes the most common primary brain tumor and carries a grim prognosis for patients treated with conventional therapy including surgery, radiation therapy, and chemotherapy. There has been a recent revival of selective intra-arterial delivery of targeted agents for the treatment of glioblastoma multiforme. Because these agents are less toxic and their delivery leads to a higher tumor-drug concentration, this combination may provide a better outcome in patients with high-grade glioma. This article discusses early experiences in patients who received superselective intra-arterial cerebral infusion of bevacizumab, cetuximab, and temozolamide after blood-brain barrier disruption with mannitol.

Original languageEnglish (US)
Pages (from-to)323-329
Number of pages7
JournalNeurosurgery clinics of North America
Volume23
Issue number2
DOIs
StatePublished - Apr 2012

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Superselective Intra-Arterial Cerebral Infusion of Novel Agents After Blood-Brain Disruption for the Treatment of Recurrent Glioblastoma Multiforme: A Technical Case Series'. Together they form a unique fingerprint.

Cite this